MedWatch

Future hope for Danish testicular cancer-test

The Danish national hospital, Rigshospitalet, and bioinformatics company Visiopharm have developed a test to detect testicular cancer through a sperm sample. The test has now been distributed to interested surrounding countries, but there are still obstacles in the way before they can market a finished product to European hospitals.

Foto: Casper Dalhoff / Jyllands-Posten

A Danish-developed test for the detection of testicular cancer through sperm samples is being put to use in Germany, Norway, Sweden and Poland.

Researchers at Rigshospitalet have found a way to identify pre-stage testicular cancer cells in a sperm sample and, backed financially by Højteknologifonden (The High Technology Fund) and working closely with the company Visiopharm, the scientists have automated the process to look for the pre-stage cells in a sperm sample under microscope – work that otherwise requires a lot of manpower.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier